Human challenge full-service solution

Protocol Design

  • Study management process
  • Services deliver quality results
  • Meeting client needs and timelines
  • Trials conducted using controlled settings and processes

Screening & recruitment

  • Recruitment of volunteers in the UK using the ‘FluCamp’ brand

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan PLC

More articles like this

Open Orphan Plc

Open Orphan swings into profit due to Covid wins

UK-based pharmaceutical company, Open Orphan reported higher profit in its six-month financial statement. Revenue grew 242% to £21.9m compared to £6.4m for the same period last year. Growth was driven by six active challenge studies in the first half

Open Orphan Plc

Open Orphan signs £5.7m human challenge study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed a £5.7m contract

Open Orphan Plc

Open Orphan 242% reported revenue growth in H1 2021

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced its unaudited interim results for the six months ended 30 June

Open Orphan Plc

What is RSV in babies?

Respiratory Syncytial Virus, commonly referred to as RSV, is a respiratory virus that causes cold-like symptoms in the typical healthy adult, which can last on average for one week. However, RSV in the elderly, babies and young children

Open Orphan Plc

Medical writing & regulatory affairs

From the early phases of development through marketing authorisation, regulatory interactions are essential to your progress and success. These exchanges will not only shape the advancement of your program, but also the value of your asset and your

Open Orphan Plc

Open Orphan positive results emerge from RSV Human Challenge Study

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has noted the announcement dated 1 September 2021 from Barvarian Nordic

Open Orphan Plc

The man who chose to get Covid

Jake Hopkins, a university student in the U.K., decided earlier this year to do something most people in the world have been trying to avoid: he volunteered to get Covid-19. Jake signed up for a human challenge trial